Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. Company
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Affimed N.V.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Number of employees : 163 people.
Sales per Business
20192020Delta
Collaboration22.0392%31.6497.9% +43.61%
Service1.918%0.692.1% -63.88%
USD in Million
Sales per region
20192020Delta
United States22.1092.3%32.1199.3% +45.28%
Germany--0.220.7%-
Europe1.847.7%0.000% -99.88%
USD in Million
Managers
Name Title Age Since
Adolf Hoess, Dr. Chief Executive Officer 58 2011
Angus W. Smith Chief Financial Officer 37 2020
Andreas Harstrick, Dr. Chief Medical Officer 59 2020
Arndt Schottelius, Dr. Chief Scientific Officer 53 2020
Wolfgang Fischer, Dr. Chief Operating Officer 56 2017
Ulrich M. Grau, Dr. Independent Member-Supervisory Board 71 2015
Bernhard R. M. Ehmer, Dr. Independent Member-Supervisory Board 65 2016
Harry Welten Independent Member-Supervisory Board 55 2020
Alexander Fudukidis Head-Investor Relations - 2020
Denise Mueller Chief Business Officer - 2016
Members of the board
Name Title Age Since
Thomas O. Hecht, Dr. Chairman-Supervisory Board 69 2014
Ulrich M. Grau, Dr. Independent Member-Supervisory Board 71 2015
Bernhard R. M. Ehmer, Dr. Independent Member-Supervisory Board 65 2016
Mathieu Simon Member-Supervisory Board 65 2018
Annalisa Mary Jenkins, Dr. Member-Supervisory Board 54 2020
Harry Welten Independent Member-Supervisory Board 55 2020
Uta Kemmerich-Keil Member-Supervisory Board 54 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 119,731,915 116,414,009 97.2% 0 0.0% 97.2%
Shareholders
NameEquities%
Ridgeback Capital Management LP 6,450,000 5.42%
Point72 Asset Management LP 5,335,903 4.49%
683 Capital Management LLC 5,265,000 4.43%
NEA Management Co. LLC 4,426,488 3.72%
Citadel Advisors LLC 4,377,426 3.68%
Granahan Investment Management, Inc. 3,676,295 3.09%
Consonance Capital Management LP 3,176,418 2.67%
Pictet Asset Management SA 3,123,751 2.63%
HealthCor Management LP 2,422,964 2.04%
SSgA Funds Management, Inc. 1,971,280 1.66%
Company contact information
Affimed NV
Technologiepark
Im Neuenheimer Feld 582
Heidelberg, Baden Wuerttemberg 69120

Phone : +49.6221.6743.60
Fax : +49.6221.67436.49
Web : http://www.affimed.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Affimed N.V.
Sector Bio Therapeutic Drugs